LibiGel Offers Hope For Post-Menopausal Women
For decades women have struggled with lack of sexual desire as well as less satisfying sexual experiences,especially for women in menopause.These conditions are known as Hypoactive Sexual Desire Disorder(HSDD)and Female Sexual Dysfunction(FSD).It is estimated that as many as 40% of women of menopause age experience one of these disorders, which can cause strain and stress to an otherwise healthy relationship. There has yet to be an FDA approved medication to treat HSDD and FSD, but this may soon change and women may soon have hope as LibiGel treatment is currently under Phase III of Clinical Trial testing. BioSante is making tremendous investments in clinical saftey trials to become FDA approved. Flibanserin was recently denied their FDA application for an NDA this year so the pressure is on.
LibiGel Clinical Trials
After a highly successful Phase II Clinical Trial that involved more than 850 women,LibiGel showed an increase in sexual desire by 230% in menopausal women.Women in Phase II Clinical Trial studies also reported more satisfying sexual experiences after using Libigel. No serious side effects were reported during Phase II Clinical Trials. Women in menopause stage showed significant improvement with the treatment of HSDD and FSD. LibiGel could be the first female libido enhancer to recieve FDA approval in the very near future. Phase III of the study involves more than 2,500 women over the course of a year. It is expected for this Clinical Trial to be successful,and FDA approval obtained within the next few years, even as early as 2012.BioSante, the creators of LibiGel,feel confident that the medication will be successful during Phase III trials and be the first and only FDA approved treatment for FSD and low libido.
How Does LibiGel Work?
LibiGel is a testostorone gel women apply to the upper arm area. Containing testostorone,the gel is easily absorbed into the skin where it can reach the bloodstream fast to raise hormone levels. A decrease in hormone levels as women age cause lack of sexual desire as well as unsatisfying sexual experiences.LibiGel works to raise these hormone levels, bringing sexual desire and satisfaction back to life once again. LibiGel is pain free and thought to be safe for use by most women who suffer from HSDD or FSD. LibiGel releases a dosage of testostorone within normalrange, the same levels shown by non-menopausal women. If LibiGel Phase III Clinical Trials go as expected,BioSante can do something no other company has. Women all across the world can find relief and comfort with LibiGel if FDA approval is obtained as expected.
Female Libido Enhancer Studies
LibiGel is the latest of a number of products being tested to increase female sexual desire. It is estimated that more than $2.5 million is spent to find a solution to this issue affecting menopausal women. LibiGel has been the most successful of all medications that have been tested.
- Written by:
- Danni Orely
